Compare DRH & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRH | TYRA |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | N/A | 2021 |
| Metric | DRH | TYRA |
|---|---|---|
| Price | $12.02 | $32.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $10.38 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 2.3M | 943.7K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $2.42 | N/A |
| P/E Ratio | $38.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.45 | $9.96 |
| 52 Week High | $12.54 | $40.65 |
| Indicator | DRH | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 58.99 |
| Support Level | $9.10 | $29.68 |
| Resistance Level | $12.54 | $33.22 |
| Average True Range (ATR) | 0.28 | 1.71 |
| MACD | -0.08 | 0.38 |
| Stochastic Oscillator | 45.88 | 89.51 |
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The company operates in one reportable segment: The hotel ownership segment, which is comprised of upper upscale and luxury chain scale hotels that offer hotel rooms, food and beverage and other ancillary guest services.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.